The Effectiveness of Varicella Vaccine in China

Fu, Chuanxi; Wang, Ming; Liang, Jing; Xu, Jianxiong; Wang, Chengbin; Bialek, Stephanie R.

doi:10.1097/inf.0b013e3181d7380e

Cited by 50 publications

(44 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four studies reported decline in VE with time since vaccination; however, the differences did not reach statistical significance. [42][43][44][45] Vazquez et al used laboratory confirmed cases and described a decline in VE for Varivax between years 1 and 2 (from 97% to 86%) after vaccination but not subsequently (up to 7 years of follow-up, 84%) 46 ; another study in the United States reported a significant decline in 1-dose VE from 94% within 5 years after vaccination to 88% for 5 to 9 years and 82% for ≥10 years after vaccination. 47 Additionally, Bayer et al in their meta-analysis of outbreak data, concluded waning immunity based on data from four studies which all showed a decrease in VE by time since vaccination (data available for an average of 4 to 6 years since…”

Section: Figurementioning

confidence: 99%

Global Varicella Vaccine Effectiveness: A Meta-analysis

et al. 2016

View full text Add to dashboard Cite

CONTEXT: Several varicella vaccines are available worldwide. Countries with a varicella vaccination program use 1-or 2-dose schedules. OBJECTIVE:We examined postlicensure estimates of varicella vaccine effectiveness (VE) among healthy children.DATA SOURCES: Systematic review and descriptive and meta-analysis of Medline, Embase, Cochrane libraries, and CINAHL databases for reports published during 1995-2014. STUDY SELECTION:Publications that reported original data on dose-specific varicella VE among immunocompetent children. DATA EXTRACTION:We used random effects meta-analysis models to obtain pooled one dose VE estimates by disease severity (all varicella and moderate/severe varicella). Within each severity category, we assessed pooled VE by vaccine and by study design. We used descriptive statistics to summarize 1-dose VE against severe disease. For 2-dose VE, we calculated pooled estimates against all varicella and by study design. RESULTS:The pooled 1-dose VE was 81% (95% confidence interval [CI]: 78%-84%) against all varicella and 98% (95% CI: 97%-99%) against moderate/severe varicella with no significant association between VE and vaccine type or study design (P > .1). For 1 dose, median VE for prevention of severe disease was 100% (mean = 99.4%). The pooled 2-dose VE against all varicella was 92% (95% CI: 88%-95%), with similar estimates by study design.LIMITATIONS: VE was assessed primarily during outbreak investigations and using clinically diagnosed varicella. CONCLUSIONS:One dose of varicella vaccine was moderately effective in preventing all varicella and highly effective in preventing moderate/severe varicella, with no differences by vaccine. The second dose adds improved protection against all varicella.a National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; and b Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland Dr Marin conceptualized and designed the study, reviewed the articles and collected the data, supervised the analysis, interpreted the data, drafted the initial manuscript, and revised the manuscript; Dr Marti conceptualized the study, reviewed part of the articles, interpreted the data, and reviewed and revised the manuscript; Ms Kambhampati carried out the meta-analyses, interpreted the data, and reviewed the manuscript; Dr Jeram conducted an initial literature review, reviewed part of the articles and collected the data, and reviewed the manuscript; Dr Seward conceptualized and designed the study, reviewed part of the articles, critically reviewed the manuscript, and interpreted the data; and all authors approved the fi nal manuscript as submitted.The fi ndings and conclusions in this report are those of the authors and do not necessarily represent the offi cial position of the Centers for Disease Control and Prevention. For authors affi liated with the World Health Organization, the authors alone are responsible for the views expressed in this publication ...

show abstract

Section: Figurementioning

confidence: 99%

Global Varicella Vaccine Effectiveness: A Meta-analysis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…2,3 This vaccine showed good short-term efficacy in clinical trials, 4 and in the first observational studies. [5][6][7] Over time, however, continued outbreaks in highly vaccinated populations and an increasing number vaccine failures 3,[8][9][10][11] led to the recommendation of a second dose. 12,13 Higher antibody titers are achieved with a second dose of varicella vaccine, 14 which suggests greater and longer lasting protection.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of one and two doses of varicella vaccine in preventing laboratory-confirmed cases in children in Navarre, Spain

Cenoz

Martínez-Artola

Guevara

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…25 For cases, only mumps vaccinations received at least 30 d before the onset of mumps disease were considered valid. For controls, we considered only doses administered up to 30 d before the date of symptom onset in the corresponding case subject.…”

Section: Methodsmentioning

confidence: 99%